Revelation Biosciences Inc.

01/18/2022 | Press release | Archived content

Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis